Antheia Inks $73M Series B Financing Round

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing.
Antheia nabs $73M for synthetic biology platform

Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of production of active pharmaceutical ingredients and key starting materials on its synthetic biology platform…
Antheia at SynBioBeta 2020

Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology community. This year’s virtual event brought together academics, industry veterans…